The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
62
Use of riboflavin 0.1% eye drops and 3mW/cm2 UVA light for 30 minutes
Use of riboflavin 0.1% eye drops and 9mW/cm2 UVA light for 10 minutes
Price Vision Group
Indianapolis, Indiana, United States
RECRUITINGcorneal neovascularization as a proportion of the total corneal area
the cornea will be photographed and morphometric image analysis software will be used to measure corneal neovascularization as a proportion of the total corneal area. The proportion measured at baseline will be compared with the proportion measured at 6 months after treatment.
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.